Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 928 participants.

Also called NCT06360458

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 928 participants (enrolled count) (from the registry)
Sponsor
Wan-Jin Chen (from the registry)
Registry
  • NCT NCT06360458
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06360458. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-01 (actual); primary completion 2025-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke
Acronym
MIRACLE
Condition
Acute Ischemic Stroke
Condition
Large Infarct Core
Intervention (Drug)
Methylprednisolone sodium succinate
Intervention (Drug)
Placebo
Lead sponsor
Wan-Jin Chen (class: other)

Record details

Record id
cardio:ct-nct06360458
Content hash
d38fe7fed1f4a14e677beeca1c42d154cb5f2da898066f41498c2531cfc4a98b